| Symbol | NXEN |
|---|---|
| Name | NEXIEN BIOPHARMA, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 80246 United States CO 4340 East Kentucky Avenue Suite 206 |
| Telephone | (303) 495-7583 |
| Fax | — |
| — | |
| Website | http://www.nexienbiopharma.com |
| Incorporation | US |
| Incorporated On | 1952 |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | M&K CPAS, PLLC; |
| Audit Status | AUDITED |
| Reporting Status | Dark: Alternative Reporting Standard |
| CIK | 0001625288 |
| Description | Nexien BioPharma Inc. is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals, in accordance with U.S. Food and Drug Administration (FDA) pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders. Nexien BioPharmas drug development strategy consists of: A. The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations; B. Conducting "freedom to operate" investigations on these conditions; C. The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents; D. Identifying the regulatory pathway with the FDA; and E. Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s). Additional info from OTC: |
New Form 15-12G - NEXIEN BIOPHARMA, INC. Filed: 2025-09-19 AccNo: 0001493152-25-014184 Size: 16 KB
Read more(38% Neutral) NEXIEN BIOPHARMA, INC. (NXEN) Reports 50% Loss Increase for 2025-03-31
Read more(38% Neutral) NEXIEN BIOPHARMA, INC. (NXEN) Reports 39% Loss Increase for 2024-12-31
Read more(38% Neutral) NEXIEN BIOPHARMA, INC. (NXEN) Reports 134% Loss Increase for 2024-09-30
Read moreNew Form NT 10-Q - NEXIEN BIOPHARMA, INC. Filed: 2024-11-14 AccNo: 0001493152-24-045731 Size: 21 KB
Read moreNew Form NT 10-K - NEXIEN BIOPHARMA, INC. Filed: 2024-09-30 AccNo: 0001493152-24-038663 Size: 21 KB
Read moreGreenberg Richard S 🟢 acquired 6.0M shares (7 derivative) of NEXIEN BIOPHARMA, INC. (NXEN) at $0.66 Transaction Date: May 23, 2024 | Filing ID: 010007
Read moreWasoff Evan L 🟢 acquired 120.0K shares (3 derivative) of NEXIEN BIOPHARMA, INC. (NXEN) at $0.66 Transaction Date: May 23, 2024 | Filing ID: 010004
Read more